Senti Biosciences Holdings, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Senti Biosciences Holdings, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
2.76
4.29
2.56
0
0.02
Research and development
22
28.1
32.2
34.4
37.6
General and administrative
21.3
38.2
37.2
26.4
26.2
Operating expenses
43.2
66.4
95.3
61
68.8
Operating income
-40.4
-62.1
-92.7
-61
-68.8
Other non-operating income
-14.9
12.4
9.32
8.25
7.34
Income tax
0
0
Income from continuing operations
-49.7
-83.4
-52.8
-61.4
Net income
-55.3
-58.2
-71.1
-52.8
-61.4
EBITDA
-39.7
-60.7
-89.2
-57.2
-65.1
EPS, basic
-190.12
-22.31
-16.01
-12.03
-2.73
EPS, diluted
-190.12
-22.31
-16.01
-12.03
-2.73
Shares, basic (weighted)
0.29
2.61
4.44
4.6
22.5
Shares, diluted (weighted)
0.29
2.61
4.44
4.6
22.5
Balance sheet
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
56
57.6
35.9
48.3
16.4
Short-term investments
0
40.9
0
Receivables
0.48
0.63
Other current assets
0.28
0.1
0.2
0.58
0
Total current assets
60.2
103
71.2
59
23.3
Property, plant and equipment
12.4
51.4
25.3
21.3
12.9
Lease right-of-use assets
20.7
18.4
16.3
13.9
11.5
Other non-current assets
0.18
0.28
0.22
0.11
0.02
Total assets
96.7
181
119
97.8
51.2
Accounts payable
5.19
1.37
1.25
1.45
2.94
Accrued liabilities
3.08
1.71
2.36
2.54
2.37
Deferred revenue
1.66
0.8
0
0
0.04
Total current liabilities
14.5
18.1
12.7
13.1
14
Lease liabilities
21
35.1
33.5
28.9
23.6
Other non-current liabilities
0
5.05
8.1
Total liabilities
36.3
53.5
52.6
47.1
45.6
Paid-in capital
3.62
301
311
323
364
Retained earnings
-115
-173
-244
-297
-359
Other comprehensive income
0
0
0
Shareholders' equity
-111
127
66.9
25.6
5.59
Total equity
-111
127
66.9
25.6
5.59
Total liabilities and equity
96.7
181
119
97.8
51.2
Shares outstanding
0.3
4.4
4.57
4.83
30.9
Cash flow statement
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-55.3
-58.2
-71.1
-52.8
-61.4
Depreciation and amortization
0.77
1.4
3.56
3.84
3.64
Stock-based compensation
2.3
16.4
9.67
1.76
5.71
Change in receivables
-0.4
-0.13
Change in payables
-0.62
0.19
-0.29
0.8
1.74
Cash from operations
-34.6
-34.9
-52.4
-41.4
-43.4
Capital expenditures
-5.54
-41.4
-12
-0.03
-0.2
Purchases of investments
0
-40.6
-18
0
Cash from investing
-5.54
-82
30.1
0.03
-0.18
Stock issued
0
0.73
0.51
1.81
3.05
Cash from financing
68.4
119
0.78
53.7
11.8
Net change in cash
28.3
1.7
-21.5
12.4
-31.9
Free cash flow
-40.2
-76.3
-64.4
-41.4
-43.6
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.33 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-149.7%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue CAGR, 3y
-82.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-78.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-64.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-47.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-34.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
389.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
105.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.83x
Current assets / current liabilities.
Quick ratio
0.41x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.41x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$1.22
Cash from operations / diluted weighted shares.
Book value per share
-$0.11
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-483.7%
Net income / market cap (the inverse of P/E).
What was Senti Biosciences Holdings, Inc.'s revenue in fiscal 2025?
Senti Biosciences Holdings, Inc. reported revenue of $22.0K for fiscal 2025.
Was Senti Biosciences Holdings, Inc. profitable in fiscal 2025?
No. It reported a net loss of $61.4M.
How much free cash flow did Senti Biosciences Holdings, Inc. generate in fiscal 2025?
Cash from operations of $43.4M minus capital expenditures of $196.0K left free cash flow of -$43.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.